How to Write a Compelling Prospectus That Tells Your Equity Story

The Hong Kong Stock Exchange’s (“HKEX”) 2024 consultation on listing reforms, which concluded in December 2024, placed a renewed emphasis on the quality of disclosure in prospectuses, particularly for issuers from emerging sectors like biotechnology, specialty technology, and SPAC de-SPAC targets. The SFC’s 2024 Enforcement Report noted that 42% of its investigation referrals stemmed from inadequate or misleading disclosure in listing documents, a figure that underscores the regulatory cost of a poorly prepared equity story. For a company navigating the Main Board or GEM listing process, the prospectus is not merely a compliance document—it is the single most important marketing and legal instrument in the offering. A prospectus that fails to articulate a coherent, verifiable equity story will not only struggle to attract institutional anchor orders but also invites post-listing regulatory scrutiny under the Securities and Futures Ordinance (“SFO”) and the Listing Rules. This article outlines the structural, narrative, and regulatory mechanics of crafting a prospectus that survives due diligence, passes HKEX vetting, and resonates with sophisticated investors.

The Structural Foundation: From Business Model to Risk Factors

Establishing a Clear Business Model with Verifiable Metrics

The core of any prospectus is the “Business” section, which must translate operational reality into an investment thesis. Under HKEX Listing Rules Chapter 11 (for the Main Board) and Chapter 20 (for GEM), the issuer must describe its business model, principal activities, and competitive strengths with sufficient granularity to allow an investor to make an informed assessment. The first step is to define the revenue model with precision—whether it is B2B SaaS subscription revenue, biotechnology licensing milestones, or manufacturing gross margins. For a PRC-based company using a Variable Interest Entity (“VIE”) structure, the prospectus must explicitly disclose the contractual arrangements, the flow of economic benefits, and the associated PRC regulatory risks, as mandated by HKEX Guidance Letter HKEX-GL94-18 (2018, updated 2023). The business model narrative should be supported by at least three years of audited financial data, presented in a consistent format that allows year-on-year comparison. Avoid vague descriptors such as “market leader” without citing a third-party market research report; the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (paragraph 5.1) requires that all material statements be factually accurate and not misleading.

Mapping the Risk Factor Hierarchy to the Equity Story

Risk factors are not a separate document but an integral part of the equity story. The HKEX Listing Rules (Chapter 11, Rule 11.07) require a dedicated section that sets out the principal risks and uncertainties facing the issuer. The most effective prospectuses structure risk factors in a hierarchy that mirrors the narrative arc of the business model: first, industry-specific risks (e.g., PRC regulatory changes for a fintech issuer); second, company-specific operational risks (e.g., key person dependency or supply chain concentration); and third, listing-specific risks (e.g., liquidity or dilution). Each risk factor should be accompanied by a mitigation strategy or a statement of how the issuer manages that risk. For example, a biotech issuer with no approved products must disclose the clinical trial failure risk, but should also reference its patent portfolio and regulatory pathway timelines. The SFC’s 2023 Thematic Review of Prospectus Disclosure found that 68% of reviewed prospectuses contained risk factors that were generic and not tailored to the issuer’s specific circumstances, a deficiency that can lead to enforcement action under section 384 of the SFO.

The Narrative Arc: Telling a Data-Driven Equity Story

From Use of Proceeds to Value Creation

The “Use of Proceeds” section is the direct link between the capital raised and the equity story. Under HKEX Listing Rules Chapter 11, Rule 11.10, the issuer must specify the intended use of proceeds by category (e.g., R&D, sales expansion, working capital) and provide a timeline for deployment. A compelling prospectus does not stop at listing percentages; it connects each allocation to a measurable outcome. For instance, if 40% of the proceeds are allocated to research and development, the prospectus should detail the specific pipeline projects, their current phase, and the anticipated milestone within 12-24 months of listing. This approach transforms a compliance table into a value creation roadmap. For a de-SPAC transaction, the prospectus must also reconcile the trust proceeds with the business combination consideration, as outlined in HKEX Listing Rules Chapter 18B. The narrative should demonstrate that the capital structure post-listing supports the stated growth strategy, whether through organic expansion or strategic acquisitions.

The Management and Shareholders Section as a Credibility Signal

Investors in Hong Kong’s Main Board and GEM listings place significant weight on the quality and track record of the management team and controlling shareholders. The prospectus must include detailed biographies of directors, senior management, and substantial shareholders, as required by Listing Rules Chapter 11, Rule 11.12. The equity story is strengthened when the management section explicitly links past experience to the current business strategy. For example, a founder with a prior successful exit in the same sector should be highlighted, but only with verifiable details such as company name, valuation, and exit date. The section should also disclose any material litigation or regulatory sanctions involving directors or controlling shareholders, as failure to do so can constitute a breach of the Listing Rules and the SFO. The SFC’s 2022 Enforcement Action against a GEM issuer for non-disclosure of a director’s prior bankruptcy serves as a cautionary example—the omission was deemed material and resulted in a suspension of trading.

Regulatory Compliance and Due Diligence

The Sponsor’s Role and the Due Diligence Process

The sponsor (保薦人) bears primary responsibility for the accuracy and completeness of the prospectus under the SFC’s Code of Conduct (paragraph 17.1-17.6). The due diligence process must be documented in a formal due diligence plan that covers all material aspects of the issuer’s business, including financials, legal compliance, intellectual property, and regulatory status. For a PRC issuer, the sponsor must conduct on-site visits and verify the VIE structure’s legality under PRC law, as per the SFC’s 2023 Circular on Cross-Border Listings. The prospectus should reflect this diligence through clear attribution of sources—for example, citing a specific legal opinion from a PRC law firm regarding the enforceability of VIE contracts. The HKEX’s Listing Committee will scrutinize the sponsor’s work papers, and any gaps in due diligence can lead to rejection of the listing application under Listing Rules Chapter 9, Rule 9.03.

Addressing Material Changes and Post-Listing Obligations

A prospectus is a forward-looking document that must account for material changes up to the date of listing. Under Listing Rules Chapter 11, Rule 11.13, the issuer must update the prospectus if any material change occurs between the date of the prospectus and the listing date. This includes changes in financial condition, regulatory status, or business operations. The equity story must be robust enough to withstand such updates without undermining the investment thesis. For example, if a key customer contract is terminated after the prospectus is filed, the issuer must consider whether to withdraw the listing or revise the prospectus to reflect the new risk. The SFC’s 2024 Enforcement Report highlighted a case where an issuer failed to disclose a material adverse change in its supply chain, leading to a fine of HKD 8 million and a suspension of the sponsor’s license. Post-listing, the prospectus serves as the baseline for ongoing disclosure obligations under the Listing Rules (Chapter 13 for Main Board, Chapter 17 for GEM), and any material deviation from the stated use of proceeds requires shareholder approval.

Practical Takeaways

• Structure the prospectus around a single, verifiable equity story that links the business model, risk factors, and use of proceeds into a coherent investment thesis, with each claim supported by audited financials or third-party research.
• Ensure that risk factors are issuer-specific and include mitigation strategies, avoiding generic boilerplate language that the SFC has flagged as inadequate in its 2023 Thematic Review.
• Disclose all material relationships and regulatory risks, particularly for VIE structures, with explicit references to PRC legal opinions and HKEX Guidance Letter GL94-18.
• Incorporate the sponsor’s due diligence findings into the prospectus narrative, attributing sources for key factual statements to demonstrate compliance with the SFC’s Code of Conduct.
• Prepare for potential material changes between filing and listing by maintaining a dynamic disclosure process that can update the prospectus without compromising the equity story’s integrity.